Table 3 Baseline laboratory and patient characteristics between Non-AKIs and AKIs

Age in months

57.00 (2.00–137.00)

59.00 (16.50–124.00)

0.68

Male, n (%)

20 (66.67)

24 (66.67)

1.00

Underlying disease, n (%)

15 (50.00)

26 (72.22)

0.06

Early SCr > base, n (%)

11 (36.67)

28 (77.78)

< 0.01

Early RAI+, n (%)

8 (26.67)

30 (83.33)

< 0.01

Early FO+, n (%)

2 (6.67)

9 (25.00)

0.04

 Serum albumin (g/L)

33.92 ± 6.09

30.38 ± 7.35

0.04

 Serum chloride (mmol/L)

102.17 ± 4.79

102.46 ± 10.66

0.89

 Serum lactate (mmol/L)

2.80 (1.65–3.87)

4.00 (2.80–9.10)

0.01

 Active partial thromboplastin time (s)

46.20 (37.05–51.77)

55.85 (48.15–76.17)

< 0.01

 Thromboplastin time (s)

16.90 (14.42–18.85)

18.85 (16.02–24.77)

0.01

 Leukocyte count (10⁹/L)

10.61 ± 18.35

13.68 ± 22.46

0.55

 Hemoglobin (g/L)

94.43 ± 29.80

85.75 ± 29.25

0.24

 Platelet count (×10⁹/L)

225.50 (30.75–316.00)

32.00 (15.00–83.25)

< 0.01

 PRISM III score

6.00 (3.00–12.00)

14.00 (12.00–18.00)

< 0.01

 PELOD-2 score

3.00 (2.00–5.25)

7.00 (4.00–9.75)

< 0.01

 Mechanical ventilation, n (%)

9 (30.00)

28 (77.78)

< 0.01

 Renal replacement therapy, n (%)

3 (10.00)

13 (36.11)

0.01

 Early VS, n (%)

9 (30.00)

29 (80.56)

< 0.01

 ICU LOS (d)

8.50 (4.00–10.00)

5.50 (4.50–8.00)

0.06

 Hospital LOS (d)

19.50 (17.00–28.25)

17.50 (5.00–24.00)

0.03

 Mortality n (%)

2 (6.67)

25 (69.44)

< 0.01